Boston Scientific Corporation (NYSE: BSX), a leading medical device company in the U.S., has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its FARAPULSE pulse field ablation system. This system includes the FARAWAVE disposable cardiac pulse field ablation catheter and the FARASTAR cardiac pulse field ablation system, collectively referred to as the FARAPULSE series products.
The FARAPULSE series products are designed to be used in conjunction, employing pulmonary vein electrical isolation to treat patients with drug-resistant, recurrent, and symptomatic paroxysmal atrial fibrillation. As the world’s first approved pulse field ablation (PFA) products for the treatment of arrhythmias, the FARAPULSE series has already received approvals in Europe and the United States. To date, these products have been used to treat over 70,000 patients globally.- Flcube.com
